What is the recommended diagnostic workup and treatment plan for a patient with suspected IgG4‑related disease?

IgG4-Related Disease: Diagnostic Workup and Treatment

IgG4-related disease (IgG4-RD) is a systemic fibro-inflammatory autoimmune condition requiring comprehensive diagnostic evaluation combining histopathology, imaging, serology, and multi-organ assessment, with glucocorticoids as first-line therapy at 0.6-0.8 mg/kg/day (typically 30-40 mg prednisone daily) for initial treatment 1.

Diagnostic Workup

Essential Diagnostic Components

The diagnosis requires integration of multiple elements—no single test is sufficient 2, 1:

Histopathological Confirmation (Most Critical)

• Dense lymphoplasmacytic infiltrate with IgG4+ plasma cells
• IgG4+/IgG+ ratio >40% AND >10 IgG4+ cells per high-power field 3
• Storiform fibrosis pattern
• Obliterative phlebitis
• Critical pitfall: Avoid bone marrow and lymph node biopsies—these sites lack storiform fibrosis and obliterative phlebitis, making them suboptimal for diagnosis 4
• Labial salivary gland biopsy is now acceptable for dacryoadenitis/sialadenitis diagnosis 3

Serological Testing

• Serum IgG4 levels (elevated in most cases, though not universally)
• Serum protein electrophoresis to assess for polyclonal hypergammaglobulinemia 4
• IgG subclass analysis

Imaging Assessment

• Organ-specific imaging based on clinical presentation
• Look for characteristic patterns: pancreatic enlargement, retroperitoneal fibrosis, salivary/lacrimal gland swelling, biliary strictures
• Multi-organ involvement assessment is essential 1

Clinical Patterns to Recognize

• Asymmetric or involvement of fewer than two pairs of glands now qualifies for diagnosis 3
• Common presentations: autoimmune pancreatitis, retroperitoneal fibrosis, tubulointerstitial nephritis, orbital disease, lymphadenopathy
• Hematologic manifestations: eosinophilia, polyclonal hypergammaglobulinemia 4

Exclusion of Mimickers (Mandatory)

Must rule out:

• Malignancy (lymphoma, plasma cell neoplasms, solid tumors)
• Multicentric Castleman disease
• Hypereosinophilic syndromes
• Other inflammatory conditions 5, 4

Treatment Algorithm

Initial Therapy

For symptomatic patients with obstructive jaundice, abdominal pain, or organ involvement 1:

Glucocorticoid Induction (First-Line)

• Starting dose: 0.6-0.8 mg/kg/day orally (typically 30-40 mg prednisone equivalent) 1
• Continue for 1 month to induce remission
• Alternative for elderly or high-risk patients: Consider 10-20 mg daily initial dose, particularly with diabetes or severe osteoporosis 6

Tapering Schedule

• Taper over 2 additional months after initial month
• Target maintenance dose: 2.5-5 mg/day (if maintenance needed) 7
• Attempt cessation within 3 years due to elderly patient population 7

Response Assessment

Evaluate at weeks 2-4 using:

• Clinical symptoms
• Biochemical markers
• Morphological/imaging changes 1

If no response within 3 months: Reconsider the diagnosis 1

Management of Relapse

Relapse occurs in approximately 30% of cases, with higher rates in perihilar/intrahepatic bile duct involvement and multi-organ disease 6.

Three treatment options for relapse 6:

1. High-dose corticosteroids tapered to maintenance (2.5-10 mg daily) PLUS steroid-sparing agent (azathioprine or mycophenolate mofetil)

2. High-dose corticosteroids without maintenance

3. Rituximab: 2 infusions of 1,000 mg, 15 days apart, every 6 months with methylprednisolone and antihistamine premedication 6

   • High initial response rates but durable remissions are rare 4
   • Effective even when immunomodulatory drugs fail 7

Maintenance Therapy Considerations

Indications for maintenance treatment:

• Multi-organ disease
• History of relapse
• Perihilar/intrahepatic bile duct involvement 6, 1

Steroid-sparing agents to consider:

• Azathioprine
• 6-mercaptopurine
• Mycophenolate mofetil
• Cyclosporine A
• Tacrolimus
• Rituximab (periodic) 6

Adjunctive Therapies

UDCA (10-15 mg/kg/day): Can be added for cholangiopathy involvement due to anticholestatic and anti-inflammatory effects, though corticosteroid-sparing effects remain unproven 6

Endoscopic intervention: For advanced fibrotic strictures unresponsive to medical therapy—balloon dilatation with short-term stenting if needed, with mandatory antibiotic prophylaxis 6

Critical Clinical Pitfalls

• Don't delay treatment: Early recognition prevents irreversible end-stage fibrosis 5
• Corticosteroid complications: Approximately 40% develop new or worsening diabetes 4—monitor closely
• Response failure associations: More fibrotic phenotype, multiple bile duct strictures, multi-organ involvement 6
• Relapse during tapering: If disease relapses during the initial 3-month treatment, add immunosuppressive drugs immediately 1
• Emerging therapies: B cell depletion with inebilizumab shows promise for glucocorticoid-sparing approaches 8